Drugs / HWK-007
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07444814 | Dec 2025 → Oct 2028 expected | endometrial cancer, ovarian cancer | Whitehawk Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HWK-007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07444814 ↗ |
| Route | Intravenous | “HWK-007 will initially be administered as an intravenous (IV) infusion every 3 weeks (Q3W)” NCT07444814 ↗ |